BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 30636370)

  • 1. CD44 standard isoform is involved in maintenance of cancer stem cells of a hepatocellular carcinoma cell line.
    Asai R; Tsuchiya H; Amisaki M; Makimoto K; Takenaga A; Sakabe T; Hoi S; Koyama S; Shiota G
    Cancer Med; 2019 Feb; 8(2):773-782. PubMed ID: 30636370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NEAT1 is Required for the Expression of the Liver Cancer Stem Cell Marker CD44.
    Koyama S; Tsuchiya H; Amisaki M; Sakaguchi H; Honjo S; Fujiwara Y; Shiota G
    Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32168951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic relevance of miR-137 in patients with hepatocellular carcinoma.
    Sakabe T; Azumi J; Umekita Y; Toriguchi K; Hatano E; Hirooka Y; Shiota G
    Liver Int; 2017 Feb; 37(2):271-279. PubMed ID: 27473646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD44 splice isoform switching determines breast cancer stem cell state.
    Zhang H; Brown RL; Wei Y; Zhao P; Liu S; Liu X; Deng Y; Hu X; Zhang J; Gao XD; Kang Y; Mercurio AM; Goel HL; Cheng C
    Genes Dev; 2019 Feb; 33(3-4):166-179. PubMed ID: 30692202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The novel interplay between CD44 standard isoform and the caspase-1/IL1B pathway to induce hepatocellular carcinoma progression.
    Li J; Zhang Y; Ruan R; He W; Qian Y
    Cell Death Dis; 2020 Nov; 11(11):961. PubMed ID: 33168816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The osteopontin-CD44 axis in hepatic cancer stem cells regulates IFN signaling and HCV replication.
    Shirasaki T; Honda M; Yamashita T; Nio K; Shimakami T; Shimizu R; Nakasyo S; Murai K; Shirasaki N; Okada H; Sakai Y; Sato T; Suzuki T; Yoshioka K; Kaneko S
    Sci Rep; 2018 Sep; 8(1):13143. PubMed ID: 30177680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The CD44std and CD44v9 subpopulations in non-tumorigenic invasive SNU-423 cells present different features of cancer stem cells.
    Aguilar-Chaparro MA; Rivera-Pineda SA; Hernández-Galdámez HV; Piña-Vázquez C; Villa-Treviño S
    Stem Cell Res; 2023 Oct; 72():103222. PubMed ID: 37844417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Standard CD44 modulates YAP1 through a positive feedback loop in hepatocellular carcinoma.
    Fan Z; Xia H; Xu H; Ma J; Zhou S; Hou W; Tang Q; Gong Q; Nie Y; Bi F
    Biomed Pharmacother; 2018 Jul; 103():147-156. PubMed ID: 29649630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rheostatic CD44 isoform expression and its association with oxidative stress in human malignant mesothelioma.
    Chew SH; Okazaki Y; Akatsuka S; Wang S; Jiang L; Ohara Y; Ito F; Saya H; Sekido Y; Toyokuni S
    Free Radic Biol Med; 2017 May; 106():91-99. PubMed ID: 28185919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Galunisertib suppresses the staminal phenotype in hepatocellular carcinoma by modulating CD44 expression.
    Rani B; Malfettone A; Dituri F; Soukupova J; Lupo L; Mancarella S; Fabregat I; Giannelli G
    Cell Death Dis; 2018 Mar; 9(3):373. PubMed ID: 29515105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor-associated macrophages produce interleukin 6 and signal via STAT3 to promote expansion of human hepatocellular carcinoma stem cells.
    Wan S; Zhao E; Kryczek I; Vatan L; Sadovskaya A; Ludema G; Simeone DM; Zou W; Welling TH
    Gastroenterology; 2014 Dec; 147(6):1393-404. PubMed ID: 25181692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The CD44 standard isoform contributes to radioresistance of pancreatic cancer cells.
    Tsubouchi K; Minami K; Hayashi N; Yokoyama Y; Mori S; Yamamoto H; Koizumi M
    J Radiat Res; 2017 Nov; 58(6):816-826. PubMed ID: 29106581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Musashi2 contributes to the maintenance of CD44v6+ liver cancer stem cells via notch1 signaling pathway.
    Wang X; Wang R; Bai S; Xiong S; Li Y; Liu M; Zhao Z; Wang Y; Zhao Y; Chen W; Billiar TR; Cheng B
    J Exp Clin Cancer Res; 2019 Dec; 38(1):505. PubMed ID: 31888685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD44 isoforms are heterogeneously expressed in breast cancer and correlate with tumor subtypes and cancer stem cell markers.
    Olsson E; Honeth G; Bendahl PO; Saal LH; Gruvberger-Saal S; Ringnér M; Vallon-Christersson J; Jönsson G; Holm K; Lövgren K; Fernö M; Grabau D; Borg A; Hegardt C
    BMC Cancer; 2011 Sep; 11():418. PubMed ID: 21957977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of tumor initiation is dependent on CD44s in c-Met⁺ hepatocellular carcinoma.
    Dang H; Steinway SN; Ding W; Rountree CB
    BMC Cancer; 2015 Mar; 15():161. PubMed ID: 25886575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FAM83D associates with high tumor recurrence after liver transplantation involving expansion of CD44+ carcinoma stem cells.
    Lin B; Chen T; Zhang Q; Lu X; Zheng Z; Ding J; Liu J; Yang Z; Geng L; Wu L; Zhou L; Zheng S
    Oncotarget; 2016 Nov; 7(47):77495-77507. PubMed ID: 27769048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protein expression of CD44 (standard and variant isoforms) in hepatocellular carcinoma: relationships with tumor grade, clinicopathologic parameters, p53 expression, and patient survival.
    Endo K; Terada T
    J Hepatol; 2000 Jan; 32(1):78-84. PubMed ID: 10673070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD44s and CD44v8-10 isoforms confer acquired resistance to osimertinib by activating the ErbB3/STAT3 signaling pathway.
    Liu YN; Tsai MF; Wu SG; Chang TH; Shih JY
    Life Sci; 2024 Jan; 336():122345. PubMed ID: 38092140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ELK3 promotes the migration and invasion of liver cancer stem cells by targeting HIF-1α.
    Lee JH; Hur W; Hong SW; Kim JH; Kim SM; Lee EB; Yoon SK
    Oncol Rep; 2017 Feb; 37(2):813-822. PubMed ID: 27959451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LSD1 Stimulates Cancer-Associated Fibroblasts to Drive Notch3-Dependent Self-Renewal of Liver Cancer Stem-like Cells.
    Liu C; Liu L; Chen X; Cheng J; Zhang H; Zhang C; Shan J; Shen J; Qian C
    Cancer Res; 2018 Feb; 78(4):938-949. PubMed ID: 29259010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.